IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

James C. Barrow et al.

Serial No.:

To Be Assigned

Case No.: 21592YP

US Nat'l Filing Date:

June 14, 2006

Int'l Appl'n No.

PCT/US2004/042173

Int'l Filing Date:

15 December 2004

For:

PHENYLAMIDE AND PYRIDYLAMIDE BETA-SECRETASE

INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S

DISEASE

MAIL STOP PCT Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT <u>UNDER 37 CFR § 1.97</u>

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT EXPRESS MAIL NO.

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed

Commissioner for Patents, P. O. Box 1450, Alexandria, Viginia, 22313-1,450

MAILED BY

Int'l Appl'n No.:

PCT/GB2004/004985

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Reference K on the accompanying PTO 1440 form was cited in the International Search Report for this application. A copy of the International Search Report is enclosed with this Information Disclosure Statement.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due. Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

John C. Todaro, Reg. No. 36,036 Attorney for Applicant

MERCK & CO., Inc. P.O. Box 2000 Rahway, New Jersey 07065-0907 (732) 594-0125

Date: June 14, 2006

1 4 Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO				COMPLETE IF KNOWN		
I	NFORMATION	DIS	CLOSURE	Application Number	To Be Assisted / 502056	
6	TO A TOTAL MARKET DAY	′ A TO	DI ICANT	Filing Date	June 14, 2006	
STATEMENT BY APPLICANT				First Named Inventor	James C. Barrow	
				Group Art Unit	To Be Assigned	
(use as many sheets as necessary)				Examiner Name	To Be Assigned	
Sheet	1	of	3	Attorney Docket Number	21592YP	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY		
	A	5,693,815		Bennett et al.	12/02/1997		
			-				

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite		Foreign Patent Documer	nt Kind	Name of Patentee or Applicant	Date of Publication of		
Initials*	No.	Office	Number	Code (if known)	of Cited Document	Cited Document MM-DD-YYYY		
	В		WO 2004/043916	PCT	Merck & Co., Inc.	05/27/2004		
	С		WO 2004/062625	PCT	Merck & Co., Inc.	07/29/2004		
	D		WO 2005/004802	PCT	Merck & Co., Inc.	01/20/2005		
	Е		WO 2005/004803	PCT	Merck & Co., Inc.	01/20/2005		
	F		WO 2005/018545	PCT	Merck & Co., Inc.	03/03/2005		
	G		WO 2005/032471	PCT	Merck & Co., Inc.	04/14/2005		
	H		WO 2005/051914	PCT	Merck & Co., Inc.	06/09/2005		
	I		WO 03/072535	PCT	Elan Pharmaceuticals, Inc.	09/04/2003		
	J		EP 1 186 305	PCT	Schering Aktiengesellschaft	03/13/2002		
	K		WO 02/02512	PCT	Elan Pharmaceuticals, Inc. and Pharmacia & Upiohn Co.			

Examiner Signature		Dat Cor	te nsidered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

AP20 Rec'd PCTspsTrue 1. 40/Seven No. 02 Department by Applicant A

					Patent and Hadelight Office, U.S DEPARTMENT OF COMMERCE	
Su	hstitute for form 1449A/PTO			COMPLETE IF KNOWN		
	NFORMATION	DIS	CLOSURE	Application Number	To Be Assigned 582856	
6	TATEMENT BY	AD	DI ICANIT	Filing Date	June 14, 2006	
3	IAIEWENI DI	Ar	PLICANI	First Named Inventor	James C. Barrow	
			,	Group Art Unit	To Be Assigned	
	(use as many sheets as necessary)			Examiner Name	To Be Assigned	
Sheet	2	of	3	Attorney Docket Number	21592YP	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY		

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Office	Foreign Patent Document Office Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
	L		WO 03/057721	(if known) PCT	Elan Phamaceuticals, Inc. and Pharmacia & Upjohn Co.	07/17/2003			
	M		WO 03/106405	PCT	Sunesis Pharmaceuticals, Inc.	12/24/2003			
	N		WO 2005/005374	PCT	Sunesis Pharmaceuticals, Inc.	01/20/2005			

Examiner Signature	Date Considered	_

Approved for use through 7/31/2006. OMB 0651-0031
Approved for use through 7/31/2006. OMB 0651-0

<u> </u>	abstitute for form 1449B/PTO			COMPLETE IF KNOWN			
INFORMATION DISCLOSURE				Application Number	To Be Assigned		
c	TO A TOTAL MEDITE DAY	7 A TO	DI ICANT	Filing Date	June 14, 2000 1582856		
STATEMENT BY APPLICANT				First Named Inventor	James C. Barrow		
			,	Group Art Unit	To Be Assigned		
(use as many sheets as necessary)			ecessary)	Examiner Name	To Be Assigned		
Sheet	3	of	3	Attorney Docket Number	21592YP		

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
,	o	C. A. Coburn et al., "Identification of a Small Molecule," J. Med. Chem., Vol. 47, pp. 6117-6119 (2004)					
	P	S. J. Stachel et al., "Structure-Based Design of Potent," J. Med. Chem., Vol. 47, pp. 6447-6450 (2004)					
	Q	S. J. Stachel et al., "Conformationally biased P3 amide replacements of beta-secretase inhibitors," Bioorganic & Medicinal Chemistry Letters, Vol. 16, pp. 641-644 (2006)					
		•					

Essentin en	Data	
Examiner Signature	Date Considered	
Oignature	 Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.